论文部分内容阅读
目的 :探讨血管紧张素转换酶抑制剂对凝血及纤溶系统的影响。方法 :急性冠状动脉综合征患者 48例 ,随机分为对照组 (1 6例 )和苯那普利组 (32例 ) ,对照组按临床常规处理 ,苯那普利组在此基础上加用苯那普利 1 0 mg/ d,分别于入院后即刻和第 3天采血测激活的凝血时间(ACT)和血浆组织型纤溶酶原激活剂 (t- PA)及其抑制物 (PAI- I)。结果 :治疗前后及组间比较ACT均无显著变化 ;两组的 t- PA活性治疗后均比治疗前明显升高 ,而 PAI- I活性明显降低 (均 P<0 .0 5及 <0 .0 1 ) ,组间比较苯那普利组升高及降低的幅度显著高于对照组 (P <0 .0 1 )。结论 :苯那普利对急性冠状动脉综合征患者的凝血系统无明显影响 ,但可使 t- PA活性增高而 PAI- I活性降低
Objective: To investigate the effect of angiotensin converting enzyme inhibitors on coagulation and fibrinolysis system. Methods: Forty-eight patients with acute coronary syndrome were randomly divided into control group (16 cases) and benazepril group (32 cases). The control group was treated routinely. The benazepril group Benazepril 10 mg / d, blood coagulation time (ACT) and plasma PAI (PAI-PA) and its inhibitor (PAI- I). Results: Before and after treatment, there was no significant difference in ACT between the two groups. The activity of t-PA in both groups was significantly higher than that before treatment and PAI-I activity was significantly decreased (both P <0.05 and <0.05). 0 1). The increases and decreases in the benazepril group were significantly higher than those in the control group (P <0.01). CONCLUSION: Benazepril has no effect on the coagulation system in patients with acute coronary syndrome, but increases t-PA activity and PAI-I activity